HC Wainwright Begins Coverage on Agios Pharmaceuticals (NASDAQ:AGIO)

Posted by Stanley Muller on Oct 29th, 2026

HC Wainwright began coverage on shares of Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) in a research report issued on Thursday, Benzinga reports. The firm set a “buy” rating and a $55.00 price target on the biopharmaceutical company’s stock. HC Wainwright‘s target price suggests a potential upside of 44.28% from the stock’s current price.

AGIO has been the subject of a number of other research reports. TD Cowen upgraded shares of Agios Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 24th. Truist Financial dropped their target price on shares of Agios Pharmaceuticals from $39.00 to $37.00 and set a “buy” rating on the stock in a research note on Wednesday, October 7th. JPMorgan Chase & Co. raised their target price on shares of Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Royal Bank Of Canada lifted their price target on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “sector perform” rating in a research note on Tuesday, July 7th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Monday, September 21st. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Agios Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $41.50.

Get Our Latest Analysis on AGIO

Agios Pharmaceuticals Trading Up 0.2%

NASDAQ:AGIO opened at $38.12 on Thursday. Agios Pharmaceuticals has a twelve month low of $22.24 and a twelve month high of $46.00. The company has a market cap of $2.28 billion, a price-to-earnings ratio of -5.44 and a beta of 0.63. The stock has a fifty day simple moving average of $33.64 and a 200-day simple moving average of $31.65.

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.04). The company had revenue of $44.75 million for the quarter, compared to analysts’ expectations of $26.39 million. Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. As a group, equities research analysts predict that Agios Pharmaceuticals will post -5.83 EPS for the current fiscal year.

Insider Activity at Agios Pharmaceuticals

In related news, insider Sarah Gheuens sold 30,000 shares of the company’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $30.48, for a total transaction of $914,400.00. Following the completion of the sale, the insider directly owned 54,645 shares in the company, valued at $1,665,579.60. This represents a 35.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 39,855 shares of company stock valued at $1,285,512. Insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. bought a new position in Agios Pharmaceuticals in the third quarter worth about $101,000. VIRGINIA RETIREMENT SYSTEMS ET Al lifted its position in shares of Agios Pharmaceuticals by 4.0% during the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 28,861 shares of the biopharmaceutical company’s stock valued at $960,000 after buying an additional 1,100 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Agios Pharmaceuticals by 15.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,893 shares of the biopharmaceutical company’s stock valued at $363,000 after buying an additional 1,428 shares during the last quarter. Inspire Investing LLC boosted its holdings in shares of Agios Pharmaceuticals by 4.7% in the 3rd quarter. Inspire Investing LLC now owns 19,130 shares of the biopharmaceutical company’s stock valued at $636,000 after buying an additional 861 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of Agios Pharmaceuticals by 1,714.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,886,412 shares of the biopharmaceutical company’s stock valued at $62,723,000 after buying an additional 1,782,457 shares in the last quarter.

Agios Pharmaceuticals Company Profile

(Get Free Report)

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.